Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis presents positive meningococcal disease vaccine data

Novartis presents positive meningococcal disease vaccine data

27th October 2010

Novartis' meningococcal disease vaccine Menveo has demonstrated its effectiveness in a new phase III clinical trial.

The pharmaceutical manufacturer has published study results which show that Menveo can help to stimulate "robust" levels of immunogenicity among infant patients against four major serogroups of the condition.

This conclusion was reached following an international trial involving more than 4,500 participants.

Novartis states that its vaccine could help to address a pressing medical need due to the sudden and potentially fatal nature of meningococcal disease, with no broad-coverage treatments for the affliction currently licensed for infants below the age of one.

Andrin Oswald, division head of Novartis Vaccines and Diagnostics, said: "As the most vulnerable age group, infants should be directly protected from this unpredictable and devastating disease."

Last week, the company published data from a six-year study of its osteoporosis treatment Acalasta, demonstrating its efficacy among postmenopausal women in the long term.ADNFCR-8000103-ID-800160084-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.